Wednesday, November 11, 2026

Micron's 2026 HBM Output Is Already Sold Out as AI Inference Drives Memory Supercycle

Micron has sold out its entire 2026 high-bandwidth memory production, with Q3 FY2026 guided revenue of ~$33.5B set to exceed any full prior year. Sandisk shares have surged over 700% year-to-date as inference workloads emerge as the fastest-growing data center demand driver. Both companies trade at forward P/E multiples of ~10-11x despite triple-digit stock gains, signaling earnings are outpacing price.

LM Salvado

June 19, 2026

Micron's 2026 HBM Output Is Already Sold Out as AI Inference Drives Memory Supercycle
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Micron's entire high-bandwidth memory (HBM) output for calendar year 2026 is sold out.1 The supply constraint reflects a structural shift: AI inference workloads are now consuming memory at a pace that production cannot match.

Micron's Q3 FY2026 guided revenue of approximately $33.5B would exceed its revenue for any full prior fiscal year.1 The company has also begun shipping HBM for Nvidia's Vera Rubin platform, signaling the next generation of AI infrastructure is already ramping.1

The demand catalyst is inference. Sandisk's CEO identified inference and reasoning workloads as the fastest-growing segment of data center demand.1 Unlike training, inference runs continuously at scale — every query to a deployed model requires memory bandwidth. As model deployments multiply, so does the sustained draw on memory supply chains.

Sandisk shares have surged over 700% year-to-date in 2026.1 Micron crossed a $1 trillion market capitalization.1 Both companies trade at forward price-to-earnings multiples of approximately 10-11x despite those gains — an unusual combination that suggests earnings growth is outrunning stock price appreciation rather than the reverse.1

The supply picture is the critical variable. When memory capacity is sold out before the year begins, pricing power shifts entirely to the supplier. Elevated HBM average selling prices flow directly to gross margins, and if supply remains constrained through 2027, that margin expansion could persist across multiple fiscal years.

The key test is whether Micron announces additional HBM capacity expansions and whether hyperscaler supply contracts are renewed or expanded at current price levels. Multi-year agreements at elevated ASPs would lock in the supercycle thesis. Quarterly gross margin trends over the next four quarters will be the clearest signal.

For data center operators, the implication is straightforward: memory availability is now a deployment bottleneck, not a procurement line item. Infrastructure teams planning AI inference capacity must account for constrained HBM supply as a scheduling variable alongside compute allocation.

The memory and storage layer, long a commodity input, has become the rate-limiting factor in AI infrastructure scaling.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com